Retinal Vessel Density and Foveal Avascular Zone Size in Psoriatic Arthritis
Official title: Evaluation of Retinal Capillary Vascular Structures and the Foveal Avascular Zone in Patients With Psoriatic Arthritis.
Run by Bursa Yuksek Ihtisas Training and Research Hospital · NCT07858591 · Data updated 2026-11-12
This study tests whether retinal blood vessel density and the size of the foveal avascular zone differ between people with psoriatic arthritis, people with psoriasis, and healthy individuals using non-invasive eye imaging.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 135 (estimated) |
| Sponsor | Bursa Yuksek Ihtisas Training and Research Hospital Government |
| Locations | 1 site (Bursa, Yıldırım) |
| Status | Recruiting |
| Started | September 1, 2026 |
| Main results expected | August 20, 2027 |
| Study ends | August 31, 2027 |
| Registry record updated | October 13, 2026 |
| Trial ID | NCT07858591 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults diagnosed with psoriatic arthritis by CASPAR criteria, adults diagnosed with psoriasis by a dermatologist, and healthy volunteers without chronic illnesses.
✕Probably not a fit
Participants with other major eye conditions or systemic illnesses not listed in the exclusion criteria may not derive direct benefit from the imaging results.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study uses Optical Coherence Tomography Angiography (OCTA) to measure retinal capillary density in the superficial, deep, and radial plexus layers, as well as the foveal avascular zone in participants. It compares patients with psoriatic arthritis, patients with psoriasis, and healthy controls to explore potential links between systemic inflammation and retinal microvasculature. The study is non-interventional and relies on imaging data to characterize ocular microcirculation. Participants are adults diagnosed by CASPAR criteria for psoriatic arthritis, with additional psoriasis patients and healthy volunteers recruited from a single hospital setting. Outcomes focus on differences in OCTA-derived metrics among groups and potential associations with disease activity.
Why it matters
Potential benefit: If successful, findings could improve understanding of how psoriatic disease affects the eye and guide future research on microvascular changes associated with systemic inflammation.
How similar studies have gone: Previous studies with OCTA have shown retinal microvascular differences in inflammatory diseases, suggesting this approach can reveal meaningful differences, though data in psoriatic disease are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Volunteers diagnosed with psoriatic arthritis according to CASPAR criteria * Volunteers diagnosed with psoriasis by a specialist dermatologist * Hospital staff or patient companions with no chronic illnesses Exclusion Criteria: * Diabetes mellitus * Cancer * Pregnancy or lactation * Chronic renal failure * Glocome * History of eye surgery * History of eye trauma
Where it's running
-
University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital
Bursa, Yıldırım, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Koray Ayar, Associated Proffessor
- Email: ayarkoray@hotmail.com
- Phone: +90 224-2955000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Is XJH05 Ointment Effective for Plaque Psoriasis?
This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.
-
HL40626S tablets in healthy adults: a first-in-human dose study
This Phase 1 study tests HL40626S tablets in healthy adults to see if it is safe, tolerated, and how it behaves in the body after single and 14-day multiple doses.
-
Global psoriasis care patterns and outcomes (observational)
This study tests how psoriasis is managed across different health systems by following patients over time to see care access, treatments, disease severity, and quality of life.
-
S-4321 in adults with autoimmune or immune-mediated diseases
This study tests S-4321 in adults with autoimmune conditions to see if it is safe and tolerable and to gather early data on how the drug behaves in the body and its initial effects on disease markers.
-
Semaglutide plus topical steroid/calcipotriol for plaque psoriasis in adults with overweight, obesity, or type 2 diabetes
This trial will test whether taking oral semaglutide along with a topical steroid/calcipotriol cream improves skin symptoms and reduces metabolic inflammation in adults with plaque psoriasis who are overweight, obese, or have type 2 diabetes.
-
Audio-based therapy to help anxiety in people with psoriasis
This study tests whether a short audio therapy session can ease anxiety in adults with psoriasis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.